Epigeneres Biotech

Epigeneres Biotech

Epigeneres, in collaboration with Tzar Labs, has developed a groundbreaking diagnostic tool for early cancer detection. This tool represents a significant advancement in the field of oncology diagnostics. Here are the key aspects of Epigeneres' offerings and approach: Innovative Cancer Detection: Epigeneres has co-developed a novel diagnostic tool that can predict the presence of cancer at asymptomatic early stages with very high sensitivity. HrC Test: Their primary product, the HrC test, is a single blood test capable of detecting all types of cancers, including solid, hematological, and soft tissue sarcomas. Early Detection and Accuracy: The HrC test can detect cancer prior to tumor formation, at pre-stage 1 (stage 0) and stage 1. Initial studies with 1,000 patients have shown an accuracy rate of over 99%. Prognostic Capability: Unique among cancer tests, the HrC test is also a prognostic tool. It can determine the risk that a patient may develop cancer within the next 12 months. Mission Statement: Dr. V. K. Tripathi, the founder of Epigeneres, emphasizes that "The only real cure for cancer is early detection." This statement underlines the company's commitment to early cancer detection and prevention. Epigeneres stands out in the medical field for its innovative approach to early cancer detection and prognosis, aiming to significantly impact cancer treatment outcomes through their advanced diagnostic technology.